Introduction

Subthreshold depression (StD) has been characterized as the presence of clinically significant depressive symptoms that do not satisfy the criteria for major depressive disorder (MDD). [1] Previous studies have shown that StD has a prevalence rate of 4.0% to 38.7%, [2–4] which is higher than that for MDD. [5,6] Despite being a precursor to MDD, [7] StD has been associated with poor quality of life, [1,7,8] poor health, [9] impaired daily activities, [2,10] considerable economic burden, [11] and mortality. [12] Of particular importance, StD has been considered an significant risk factor for developing MDD given that many individuals with StD develop sustained depressive symptoms and are expected to progress to MDD. [5,13,14] Moreover, MDD is likely to recur once established and often tends to be resistant to treatment. [15] Therefore, intervention for StD is important to prevent the onset of MDD.

Previous studies have confirmed that several interventions are effective against StD. [16–22] However, current reports have shown that medical costs for StD are nearing those for MDD. [11] In addition, individuals with StD are believed to have poor motivation for intensive treatment. [19] Considering the aforementioned limitations, alternative strategies that can easily relieve depressive symptoms among individuals with StD are needed. The SPSRS application we have developed, which is designed to improve depressive symptoms among individuals with StD by presenting positive words through video viewing, can address these issues and shed new light on StD treatment. [23]
application interventions aim to relieve depressive symptoms, thereby preventing progression to MDD and helping users manage their own health. Give that the SPSRS application uses the YouTube Application Programming Interface, users are able to select a favorite video and work on reducing depression symptoms while having fun. Moreover, considering that users need not change their daily routine (e.g., commuting to work), the SPSRS application creates an opportunity for addressing problems related to face-to-face treatment, which ultimately provides substantial benefits to the insurance system and society in general. Hence, we assume that SPSRS applications have great potential as new interventions for individuals with StD given that they reduce the psychological burden of an intervention. Although our previous study showed that SPSRS application interventions improved depressive symptoms among individuals with StD, it only compared outcomes before and after the intervention within a single group without establishing a control group.[23] Therefore, randomized controlled trials (RCTs) based on rigorous methodology are essential to confirm the effectiveness of SPSRS applications for individuals with StD. However, to implement and achieve a high quality RCT, several methodological issues need to be considered and addressed (participant recruitment, administrative problems, harm, etc).[24,25] In fact, reports have shown that several methodological issues have caused one-quarter of RCTs to be discontinued early.[23] One of the best approaches for avoiding failure of a full-scale RCT has been to conduct a pilot RCT.[24,27] Accordingly, a pilot RCT can determine the feasibility of a full-scale RCT, increase the likelihood of its success, and prevent failure.[24] Therefore, we herein outline our study protocol for a pilot RCT to investigate the utility of SPSRS application interventions for individuals with StD.

2. Objective

The present study aimed to determine the feasibility of a future full-scale RCT that will investigate whether SPSRS application interventions could improve depressive symptoms among individuals with StD relative to those receiving no intervention.

2.1. Trial design

This 5-week, single-blind, 2-arm, parallel-group, randomized, pilot RCT will determine the effectiveness of with the SPSRS application by comparing individuals who had and had not been exposed to the same.

3. Methods

3.1. Eligibility criteria

Participants will be selected according to the following eligibility criteria:

Inclusion criteria:

(1) Men and women
(2) 18 years and older
(3) Center for epidemiologic studies depression scale (CES-D) score ≥16.[28]
(4) Owns a smartphone with an iOS operating system.
(5) Written informed consent prior to participation.

Exclusion criteria:

(1) Lifetime history of psychiatric disorders.
(2) Currently receiving treatment for a mental health problem from a mental health professional.
(3) Vision or hearing deficits that negatively impact everyday life.
(4) Experience of a major depressive episode 2 weeks prior to the study ascertainment using the Mini-International Neuropsychiatric Interview (MINI).[29]

3.2. Interventions

3.2.1. Experimental group.

The experimental group included herein will be scheduled to receive video viewing intervention using the SPSRS application designed for iPhones.[23] The SPSRS application is a free video viewing application that uses the YouTube API, which allows individuals to search and watch videos using keywords, similar to a general video playback application. The SPSRS application is programmed to randomly display words that increase confidence, such as “can,” “let us try,” “good luck,” “able,” and “do not worry,” for 17 ms at the 4 corners of the screen.[6] Thereafter, positive words, such as “nice,” “great,” “fantastic,” “satisfactory,” and “enjoyable,” are repeatedly displayed at the center of the screen for 150 ms every 5 seconds.[30] The experimental group will receive a video viewing intervention using the SPSRS application for >10 minutes a day (>70 minutes per week). Given that the intervention period is scheduled for 5 weeks, the experimental group will be receiving >350 minutes of video viewing intervention using the SPSRS application. Moreover, participants included herein will be able to freely select the videos to watch.

3.2.2. Control group.

The control group will receive no intervention and no instruction to watch videos using the SPSRS application or other video playback applications during the 5-week intervention period.

3.2.3. Criteria for discontinuing or modifying allocated interventions.

The intervention or follow-up is discontinued if any of the following occurs:

(1) Participant withdraws consent.
(2) The entire clinical trial is discontinued.
(3) Non-eligibility is confirmed after registration.
(4) The principal investigator or project administrator determines the need for discontinuation.

A participant requires treatment for a mental health problem by a mental health professional following hospitalization or the onset of a mental disorder.

The date and reason for discontinuation will be documented in the case report. Participants will also be invited to participate in an outcome-related assessment to determine the effectiveness of the intervention. Participants who refuse to participate in follow-up measurements, provide data, or give consent will be considered withdrawn.

3.3. Strategies for monitoring and improving intervention protocol adherence

The amount of time participants spend on viewing videos during the intervention will be recorded in the history function of the SPSRS application and will be used for treatment adherence monitoring once a week. Participants who achieve the required video viewing duration per week (i.e., ≥70 minutes) will receive a text message to encourage continued video viewing. However, those who did not meet the required video viewing duration per
week will receive a text message informing them regarding the same. In addition, a text message will be sent requesting the participant to make up for the missed viewing time on the subsequent week. Moreover, daily text messages will be sent to encourage the use of the SPSRS application and increase intervention adherence rates.

3.4. Relevant concomitant care and interventions permitted/prohibited during the trial

From an ethical point of view, no other intervention restrictions will be imposed in this study.

3.5. Outcomes

The primary outcome will include changes in the CES-D score\cite{28} after the 5-week intervention, while the secondary outcome will include changes in the Kessler Screening Scale for psychological distress (K6)\cite{31} and the generalized anxiety disorder 7-item scale (GAD-7)\cite{32} score following the 5-week intervention.

3.6. Participant timeline

Individuals interested in participating in this study will be assessed for eligibility using interviews and Internet questionnaires. Eligible participants will then be enrolled in the study and randomly assigned to the intervention or control group. The trial period is shown in the consolidated standards of reporting trials diagram\cite{33} (Fig. 1) and Standard Protocol Items: Recommendations for Interventional Trials template\cite{34} (Table 1).

3.7. Sample size

Four factors are required to calculate the sample size: significance level, power, difference between groups, and standard deviation.

| Timepoint | Enrolment | Baseline | Allocation | Intervention |
|-----------|-----------|----------|------------|--------------|
| Enrolment: | Eligibility screen X | Informed consent X | Allocation X | |
| Interventions: | Experimental group → | Control group → | |
| Assessments: | Demographics X | CES-D X | K6 X | GAD-7 X |

CES-D = the center for epidemiologic studies depression scale, GAD-7 = the generalized anxiety disorder 7-item scale, K6 = the Kessler Screening Scale for psychological distress.

![Figure 1. CONSORT flowchart of the study design.](image-url)
3.9. Allocation

contacted for further information on the study. Dedicated email address through which the research team may be

In addition, participants will be provided a dedicated email address, through which they may raise their concerns regarding the use of the SPSRS application and outcome measurements will be free of cost.

3.10. Blinding

Considering the unique nature of the intervention, participants and therapists cannot be blinded. Therefore, this trial will employ an Internet questionnaire to blind the assessors.

3.11. Data collection

Before the intervention begins, participants in the experimental group will be provided with a standardized SPSRS application manual and will be trained on how to operate the SPSRS application. To ensure data accuracy and reliability, researchers will undergo training sessions on data collection and storage. In addition, regular meetings will be held to address issues related to trial implementation. Outcome evaluation will follow the schedule outlined in Table 1. Demographic data, such as age, sex, sleep time, smoking habits, exercise habits, and drinking habits, will then be collected as part of the baseline assessment.

3.11.1. Mini-internationa neuropsychiatric interview. The mini-international neuropsychiatric interview (MINI) is structured based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition and International statistical classification of diseases and related health problems, 10th revision. The present study will use the Japanese version of the latest MINI (3.0.0), which contains 16 modules for psychiatric diagnosis (major depressive episodes, dysthymia, suicide risk, manic and hypomanic episodes, panic disorders, agoraphobia, social phobia, obsessive–compulsive disorder, posttraumatic stress disorder, alcohol use disorder, substance use disorder, psychotic disorder, anorexia nervosa, bulimia nervosa, generalized anxiety disorder, and antisocial personality disorder), to which respondents may answer with only “Yes” or “No.” The reliability and validity of the Japanese version of the MINI have already been confirmed.

3.11.2. Center for epidemiologic studies depression scale. The CES-D is a 20-item self-reported questionnaire that measures depressive symptoms using 4 subscales related to “somatic and retarded activity,” “depressed affect,” “positive affect,” and “interpersonal problems.” The CES-D uses a 4-point Likert scale (A = <1 day, B = 1–2 days, C = 3–4 days, and D = 5–7 days), with each item being scored 0 to 3, respectively. Participants may have a total score of 0 to 60 points, with a higher score indicating stronger depressive symptoms. The reliability and validity of CES-D have already been verified.

3.11.3. Kessler screening scale for psychological distress. The K6 is a 6-item self-report questionnaire that measures psychological distress using 4 questions about depression and 2 about anxiety. The K6 uses a 5-point Likert scale (0 = not at all sure, 1 = several days, 2 = over half the days, 3 = nearly every day), with a total score of 0 to 24 points, with a higher score indicating stronger psychological distress. The reliability and validity of the K6 have already been verified.

3.11.4. The generalized anxiety disorder 7-item scale. The GAD-7 is a 7-item self-report questionnaire that measures generalized anxiety disorder using a 4-point Likert scale (0 = not at all, 1 = several days, 2 = over half the days, 3 = nearly every day). Participants may have a total score of 0 to 21 points with a higher score indicating stronger anxiety symptoms. The reliability and validity of GAD-7 have already been verified.

3.12. Promoting participant retention and completion of follow-up

Participants will be informed that the use of the SPSRS application and outcome measurements will be free of cost and that the SPSRS application will allow them to freely select videos to watch so that they can enjoy the intervention. In addition, participants will be provided with a dedicated email address through which they may raise their concerns regarding the use of the SPSRS application. Moreover and if necessary, participants in the control group can receive video viewing interventions using the same SPSRS application after measuring outcomes 5 weeks following the start of the intervention. Outcome measurements will be conducted through an easy-to-use Internet questionnaire for the participant’s convenience. Participants who satisfy the criteria for refusal or discontinuation of intervention will be
asked to participate and provide data for the week 5 assessment. The aforementioned requests and responses will be explained to participants upon obtaining informed consent. No financial or physical incentives will be provided to participants at any point during the evaluation or intervention.

3.13. Data management

Data will be managed in accordance with methods used in previous studies. Accordingly, first and second stage management will be implemented to ensure data accuracy. First stage management will require 2 independent researchers to enter data into an Excel spreadsheet using a computer not connected to the Internet. The input data will then be saved onto a password-protected Universal Serial Bus. Second stage management will require 2 different researchers not involved in the first stage to confirm and double-check for any potential errors in the input contents. Only individuals authorized by the principal investigator will be allowed access to the database. The Internet questionnaire data of each participant will be printed on paper and deleted after data entry. Paper materials related to each participant’s evaluation will be stored in an evaluator binder, while intervention materials will be stored in a separate intervention binder. Binders that store evaluation and intervention forms will be kept inside a lockable shelf at Kibi International University. Paper files will be stored for up to 5 years after the examination ends.

3.14. Statistical methods

Intention-to-treat analysis will be employed herein using data obtained from all assigned participants. A linear mixed models with the restricted maximum likelihood estimation method will then be used to address values missing from the clinical trial, estimate the mean of the primary and secondary outcomes, and compare the experimental and control groups. Group assignment, evaluation time, and interactions between group assignment and evaluation time will be considered fixed effect factors, while participants will be considered random effect factors. The model will use a fixed effect type III test. A 2-sided P value of <.05 will be used to indicate statistical significance. No plans for subgroup analysis are currently in place. The latest version of SPSS (SPSS Japan Inc., Tokyo, Japan) will be used for data analysis. In addition, the effect size (Hedge’s g) between the 2 groups and its 95% confidence interval will also be reported.

3.15. Data monitoring

This pilot RCT has been designed for conciseness and minimizing risk. Therefore, no formal data monitoring committee has been organized. In addition, no interim analysis of the intervention’s impact has been planned at this stage.

3.16. Harm

Previous studies have reported no adverse events with the use of the SPSSR application. However, adverse events will be systematically monitored based on the methods used in previous studies, while prompt responses will be provided for incidences and signs of adverse events. Participants are encouraged to identify signs of mental or physical health deterioration upon study enrollment, regardless of whether they participate the intervention. The appearance of such symptoms will be considered an adverse event.

Participants will be taught 2 methods of identifying adverse events during and after the study. First, participants will be encouraged to talk to their researchers upon noticing signs of mental or physical health deterioration. Second, all study participants will be requested to inform the research team whether and why they plan to discontinue with the study. Upon the occurrence of an adverse event, the participant will be contacted and appropriate action will be taken. The investigator will also evaluate and document the participant’s relationship with the study in addition to the content, duration, severity, and outcome of the adverse event.

Details regarding adverse events will be immediately reported to the Kibi International University Ethics Review Board who will then determine the direction of the study.

3.17. Auditing

No audit has been planned at this time.

3.18. Research ethics approval, protocol amendments, and consent

This trial has been approved by the Ethics Review Committee of Kibi International University (approval number: 19-33). Prior to participation, the principal investigator or collaborators will inform the participants regarding the details of this trial using trial information materials. Changes to the study protocol will require approval from the Kibi International University Ethics Review Board. Before obtaining informed consent, the researchers will briefly explain the potential risks and benefits of study participation. Documentation of the participants’ satisfaction with the risks and benefits is essential. The researchers will also inform participants that participation is optional and can be discontinued at any time. Informed consent, which will be presented through an Internet questionnaire and obtained by pressing the consent button when the participant agrees to participate in the trial, will be obtained before any intervention is provided.

3.19. Confidentiality

All information related to the study will be stored securely at Kibi International University. Paper documents will be stored separately for each participant. All survey materials will be identified using participant numbers and stored inside a lockable shelf to maintain participant confidentiality. Information that could potentially identify a participant, such as informed consent, will be kept separate from the survey material identified using participant numbers. The electronic database will be stored on a password-protected Universal Serial Bus and stored together with the paper survey materials. Information regarding a participant’s identity will not be entered into the electronic database. Data input and statistical analysis will be conducted on a computer not connected to the Internet at Kibi International University.

3.20. Access to data

Prior to the publication of major results, only data managers and principal investigators will have access to the complete dataset. Data managers and principal investigators will address problems related to the data and finalize a dataset for statistical analysis. After publication, only the principal investigator and individuals approved by the principal investigator will have access to the dataset.
3.21. Ancillary and post-trial care

Participants will be able to contact the researchers during the trial period or until 1 month after the end of participation. This trial cannot guarantee the absence of unexpected serious adverse events during and after the participation period. Participants who develop serious adverse events will be responded to promptly and appropriately even after study completion.

3.22. Dissemination policy

Regardless of the outcome, the trial results will be published in a peer-reviewed journal. Furthermore, participating in and presentations at relevant national and international academic conventions can further promote dissemination.

4. Discussion

StD has been considered an important risk factor for the development of MDD. [5,13,14] Moreover, despite being a precursor to MDD, [7] StD has been associated with poor quality of life, [17,7,8] poor health, [9] impaired daily activities, [2,10] economic costs, [11] mortality, [12] etc. Therefore, interventions aimed at addressing StD are important to prevent the onset of MDD. Incorporating the SPSRS application into interventions is a very innovative method that places less burden on individuals with StD and may improve depressive symptoms. In addition, given the potential for the SPSRS application to influence numerous individuals with StD, it may play an important role in addressing depressive symptoms that may have a significant negative impact on their health. However, RCTs using the SPSRS application for individuals with StD have been lacking. Therefore, a pilot RCT investigating the feasibility of a large-scale trial to determine the effectiveness of the SPSRS application had been planned. The results of this pilot RCT will undoubtedly ensure the successful implementation of a full-scale RCT. In addition, this pilot trial will provide new information through which a higher-quality full-scale RCT can be planned. A particularly important additional information obtained from results of this pilot RCT is that related to the official sample size calculation. Thus, this pilot RCT can provide evidence that reinforces the standard practice of SPSRS application interventions to improve depressive symptoms among individuals with StD. This study, however, is not without limitations. First, this pilot study will utilize simple randomization. As a result, other demographic factors, such as age, can lead to sample heterogeneity. Future studies will need to consider stratification of various demographic factors. Second, given the restrictions on the use of the SPSRS application, participants must own an iPhone, thereby excluding those using smartphones running on other operating systems (such as Android). Therefore, our research results may not be generalized to all individuals with StD people. However, we plan to make the SPSRS application compatible with other smartphones (such as Android) for future research, which would considerably increase the number of potential participants. Third, a formal sample size calculation could not be performed given that lack of data on the use of the SPSRS application. This lack of sample size calculation may decrease the power of this pilot RCT. However, retrospective sample size calculation will be performed after this trial. Finally, given the nature of this study, participant and therapist blinding will be difficult. Therefore, some therapist and participant biases may be present. However, we will endeavor to mitigate potential biases resulting from the lack of blinding. For example, research hypotheses will be concealed and standardized intervention guidance and textual feedback will be provided to maintain data quality. Considering the aforementioned limitations, care should be taken in the interpretation of this pilot study’s results.

5. Conclusion

This pilot RCT will have been the first to explore the utility of SPSRS application interventions, which display positive words in videos, for individuals with StD. The results of this pilot RCT are expected to help in the design and implementation of a full-scale RCT investigating the effects of the SPSRS application among individuals with StD.

Author contributions

Conceptualization: Yudai Kato, Kaito Kageyama, Takanori Mesaki, Hiroyuki Uchida, Kazuki Hirao.
Data curation: Yudai Kato, Kaito Kageyama, Takanori Mesaki.
Formal analysis: Hiroyuki Uchida, Kazuki Hirao.
Funding acquisition: Kazuki Hirao.
Investigation: Yudai Kato, Kaito Kageyama, Takanori Mesaki, Yoshiyuki Seijima, Risako Marume, Kana Takahashi.
Methodology: Hiroyuki Uchida, Kazuki Hirao.
Project administration: Kazuki Hirao.
Supervision: Kazuki Hirao.
Writing – original draft: Hiroyuki Uchida, Kazuki Hirao.
Writing – review & editing: Yudai Kato, Kaito Kageyama, Takanori Mesaki, Hiroyuki Uchida, Yoshiyuki Seijima, Risako Marume, Kana Takahashi, Kazuki Hirao.
Kazuki Hirao orcid: 0000-0002-2467-7564.

References

[1] Rodriguez MR, Nuevo R, Chatterji S, et al. Definitions and factors associated with subthreshold depressive conditions: a systematic review. BMC Psychiatry 2012;12:181.
[2] Xiang X, Leggett A, Himle JA, et al. Major depression and subthreshold depression among older adults receiving home care. Am J Geriatr Psychiatry 2018;26:9:39–49.
[3] Meeks TW, Vahia IV, Lavretsky H, et al. A tune in “a minor” can “b major”: a review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. J Affect Disord 2011;12:126–42.
[4] Vaccaro R, Borrelli P, Abbondanza S, et al. Subthreshold depression and clinically significant depression in an Italian population of 70-74-year-olds: prevalence and association with perceptions of self. BioMed Res Int 2017;2017:3592359.
[5] Naber D, Bullinger M. Should antidepressants be used in minor depression? Dialogues Clin Neurosci 2018;20:223–8.
[6] Takahashi K, Takada K, Inoue A, et al. Identification of common words to improve self-confidence in Japanese students with subthreshold depression. Int J Adolesc Med Health 2019;31:1–7.
[7] Cuijpers P, Smir F, van Straten A. Psychological treatments of subthreshold depression: a meta-analytic review. Acta Psychiatr Scand 2007;115:434–41.
[8] Goldney RD, Fisher LJ, Dal Grande E, et al. Subsyndromal depression: prevalence, use of health services and quality of life in an Australian population. Soc Psychiatry Psychiatr Epidemiol 2004;39:293–8.
[9] Ayuso-Mateos JL, Nuevo R, Verdes E, et al. From depressive symptoms to depressive disorders: the relevance of thresholds. Br J Psychiatry 2010;196:365–71.
[10] Rucci P, Gherardi S, Tanella M, et al. Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. J Affect Disord 2003;76:171–81.
[11] Cuijpers P, Smits F, Oostenbrink J, et al. Economic costs of minor depression: a population-based study. Acta Psychiatr Scand 2007;115: 229–36.
[12] Ho C, Jin A, Nyunt MS, et al. Mortality rates in major and subthreshold depression: 10-year follow-up of a Singaporean population cohort of older adults. Postgrad Med 2016;128:642–7.
[13] Wesselhoft R, Sorensen MJ, Heirvanger ER, et al. Subthreshold depression in children and adolescents - a systematic review. J Affect Disord 2013;151:7–22.
[14] Lee YY, Stockings EA, Harris MG, et al. The risk of developing major depression among individuals with subthreshold depression: a systematic review and meta-analysis of longitudinal cohort studies. Psychol Med 2019;49:92–102.
[15] Narang P, Rettzlaff A, Brar K, et al. Deep brain stimulation for treatment-refractory depression. South Med J 2016;109:700–3.
[16] Mori A, Okamoto Y, Okada G, et al. Behavioral activation can normalize neural hyperactivation in subthreshold depression during a monetary incentive delay task. J Affect Disord 2016;189:234–62.
[17] Shores MM, Kivlahan DR, Sadak TI, et al. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009;70:1009–16.
[18] Wong SYS, Sun YY, Chan ATY, et al. Treating subthreshold depression in children and adolescents - a systematic review. Early Interv Psychiatry 2019;13:133–6.
[19] Alturki R, Schandelmaier S, Olu KK, et al. Premature trial discontinuation often not accurately reported in registries: comparison of registry records with publications. J Clin Epidemiol 2017;81:56–63.
[20] Kasenda B, von Elm E, You J, et al. Prevention, characteristics, and publication of discontinued randomized trials. JAMA 2014;311: 1045–51.
[21] Ilieva A, Li, MAP, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol 2010;10:61.
[22] Briel M, Olu KK, von Elm E, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol 2016;69:80–15.
[23] Shima S, Shikano T, Kitamura T, et al. New self-rating scale for depression: The CASPER Randomized Clinical Trial. JAMA Psychiatry 2016;16:336.
[24] Barbui C, Cipriani A, Patel V, et al. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry 2011;198:11–6. sup 1.
[25] Handelsman S, Lewis H, Adamson J, et al. Effect of collaborative care vs usual care on depressive symptoms in older adults with subthreshold depression: The CASPER Randomized Clinical Trial. JAMA 2017;317:728–37.
[26] Furukawa TA, Horikoshi M, Kawakami N, et al. Telephone cognitive-behavioral therapy for subthreshold depression and presenteeism in workplace: a randomized controlled trial. PLoS One 2012;7:e35330.
[27] Takahashi K, Takada K, Hirao K. Feasibility and preliminary efficacy of a smartphone application intervention for subthreshold depression. Early Interv Psychiatry 2019;13:133–6.
[28] Alturki R, Schandelmaier S, Olu KK, et al. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications. J Clin Epidemiol 2017;81:56–63.
[29] Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:e1–37.
[30] Furukawa TA, Kawakami N, Saitoh M, et al. The performance of the Mini-International Neuropsychiatric Interview. Psychiatry Clin Neurosci 2005;59:517–26.
[31] Takarada Y, Nozaki D. Maximal voluntary force strengthened by the enhancement of motor system state through barely visible priming words with reward. PLoS One 2014;9:e109422.
[32] Spitzer RL, Kroenke K, Williams JB, et al. A short measure for assessing depression: the GAD-7. Arch Intern Med 2006;166: 1092–7.
[33] Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;336:b286.
[34] Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346: e5386.
[35] Charles P, Giraud B, Dechartres A, et al. Reporting of sample size calculation in randomised controlled trials: review. BMJ 2009;338: b1732.
[36] Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health 2008;31:180–91.
[37] Ohn S, Takahashi K, Inoue A, et al. Smallest detectable change and test-retest reliability of a self-reported outcome measure: results of the Center for Epidemiologic Studies Depression Scale, General Self-Efficacy Scale, and 12-item General Health Questionnaire. J Eval Clin Pract 2017;23:1548–54.
[38] Shima S, Katagaya Y, Kitamura T, et al. Poststroke depression. Gen Hosp Psychiatry 1994;16:286–9.
[39] Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med 2002;32:959–76.
[40] Hajebi A, Motieyanal A, Amin-Esmaeili M, et al. Adaptation and validation of short scales for assessment of psychological distress in Iran: the Persian K10 and K6. Int J Methods Psychiatr Res 2017;26:1726.
[41] Iwasa H, Takebayashi Y, Suzuki Y, et al. Psychometric evaluation of the simplified Japanese version of the Athens Insomnia Scale: The Fukushima Health Management Survey. J Sleep Res 2019;28:e12771.
[42] Saito T, Nagamine M, Shigemura J, et al. Construct validity and reliability of the Tachakawa Resilience Scale in the Japanese ground self-defense force personnel. Neuropsychiatr Dis Treat 2018;14:2505–10.
[43] Shima S, Kitagawa Y, Kitamura T, et al. Smallest detectable change and test-retest reliability of a self-reported outcome measure: results of the Center for Epidemiologic Studies Depression Scale, General Self-Efficacy Scale, and 12-item General Health Questionnaire. J Eval Clin Pract 2017;23:1548–54.
[44] Ohn S, Takahashi K, Inoue A, et al. Smallest detectable change and test-retest reliability of a self-reported outcome measure: results of the Center for Epidemiologic Studies Depression Scale, General Self-Efficacy Scale, and 12-item General Health Questionnaire. J Eval Clin Pract 2017;23:1548–54.
[45] Umeda M, Kawakami N. Cross-cultural measurement equivalence of the Japanese version of Revised Conflict Tactics Scales Short Form among Japanese men and women. Psychiatry Clin Neurosci 2014;68:804–11.
[46] Sawaya H, Arout M, Hamedeh A, et al. Adaptation and initial validation of the Patient Health Questionnaire - 9 (PHQ-9) and the Generalized Anxiety Disorder - 7 Questionnaire (GAD-7) in an Arabic speaking Lebanese psychiatric outpatient sample. Psychiatr Res 2016;239:245–52.
[47] Sousa TV, Viveros V, Chai MV, et al. Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale. Health Qual Life Outcomes 2015;13:50.
[48] Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317–25.
[49] Lowe B, Decker O, Muller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 2008;46:266–74.
[50] Cai Y, Zhang CS, Ouyang W, et al. Electroacupuncture for poststroke spasticity (EAPSS): protocol for a randomised controlled trial. BMJ Open 2018;8:e017912.
[51] Fang J, Chen L, Chen L, et al. Integrative medicine for subacute stroke rehabilitation: a study protocol for a multicentre, randomised, controlled trial. BMJ Open 2014;4:e007080.
[52] Chen L, Fang J, Jin X, et al. Acupuncture treatment for ischaemic stroke in young adults: protocol for a randomised, sham-controlled clinical trial. BMJ Open 2016;6:e010073.
[53] Kuerguvela R, Kristal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004;61:310–7.
[54] Hedges LV. Distribution theory for Glass’s estimator of effect size and related estimators. J Educ Stat 1981;6:107–28.
[55] Galante J, Dufour G, Benton A, et al. Protocol for the Mindful Student Intervention: a randomised controlled trial of the provision of a mindfulness intervention to support university students’ well-being and resilience to stress. BMJ Open 2016;6:e012300.